Efficacy of Ustekinumab for the treatment of perianal fistulizing Crohn’s disease: a multicentre retrospective study - Top-Institutions - MDSpire

Efficacy of Ustekinumab for the treatment of perianal fistulizing Crohn’s disease: a multicentre retrospective study

  • By

  • Youran Li

  • Xiaomei Sun

  • Ke Wen

  • Lu Lu

  • Wei Wang

  • Minna Wu

  • Jiaze Ma

  • Zailong Zhou

  • Yunfei Gu

  • July 10, 2026

  • 0 min

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    Affiliated Hospital of Nanjing University of Chinese Medicine
    Affiliated Hospital of Nanjing University of Chinese Medicine

    Nanjing, Jiangsu

    Key Differentiators

    • Gastroenterology

  • #2

    Jiangsu Provincial Hospital of Traditional Chinese Medicine
    Jiangsu Provincial Hospital of Traditional Chinese Medicine

    Nanjing, Jiangsu

    Key Differentiators

    • Gastroenterology

  • #3

    Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine
    Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine

    Shanghai, Shanghai

    Key Differentiators

    • Gastroenterology

  • #4

    First Affiliated Hospital of Anhui University of Chinese Medicine
    First Affiliated Hospital of Anhui University of Chinese Medicine

    Hefei, Anhui

    Key Differentiators

    • Gastroenterology

  • #5

    Beijing Anorectal Hospital
    Beijing Anorectal Hospital

    Beijing, Beijing

    Key Differentiators

    • Gastroenterology

Original Source(s)

Efficacy of Ustekinumab for the treatment of perianal fistulizing Crohn’s disease: a multicentre retrospective study

  • by Youran Li, Xiaomei Sun, Ke Wen, Lu Lu, Wei Wang, Minna Wu, Jiaze Ma, Zailong Zhou, Yunfei Gu

  • July 10, 2026

Related Content

UCI Health hosts IBD transition of care open house

UCI Health hosted a World IBD Day open house designed to support young adults with inflammatory bowel disease.

  • by

  • June 19, 2026

  • 1 min
Editorial: Community series in towards precision medicine for immune-mediated disorders: advances in using big data and artificial intelligence to understand heterogeneity in inflammatory responses, volume III

Integrative single-cell transcriptomics and mendelian randomization identifies BTN3A2 as a shared protective factor in Behçet’s disease and inflammatory bowel disease